Dual therapy based on raltegravir and boosted protease inhibitors - the experience of Polish centers.
Arch Med Sci
; 14(4): 860-864, 2018 Jun.
Article
em En
| MEDLINE
| ID: mdl-30002705
ABSTRACT
INTRODUCTION:
The aim of the study was to present the experience of Polish centers regarding dual therapy based on the integrase inhibitor raltegravir (RAL) and ritonavir-boosted protease inhibitors (PI/r) for treating treatment-naïve and -experienced HIV-infected patients. MATERIAL ANDMETHODS:
The paper concerns a retrospective multicenter study. The medical databases of six main Polish HIV centers from January 2009 to December 2014 were analyzed for the use of combined antiretroviral treatment consisting of RAL + PI/r. This study included 126 HIV-infected patients receiving RAL + PI/r therapy, of whom 17 patients were treatment-naive and 109 patients were treatment-experienced.RESULTS:
In treatment-experienced patients, the most common reasons for the introduction of a RAL + PI/r regimen were virologic failure and impaired renal function (45 of 109 patients). In the treatment-naïve group kidney disease was the cause of the RAL + PI/r regimen in 3 of 17 participants. In treatment-experienced patients, 80% of individuals still were on RAL + PI/r treatment after 12 months, 65% after 24 months and 53% of subjects after 60 months. In both groups, the simplification of the antiretroviral regimen was the most common reason for discontinuation of RAL + PI/r based therapy.CONCLUSIONS:
In antiretroviral-experienced patients the dual therapy based on RAL + PI/s is safe and effective. In antiretroviral-naïve patients the RAL + PI/r regimen is rarely used in Poland.
Texto completo:
1
Bases de dados:
MEDLINE
Tipo de estudo:
Clinical_trials
Idioma:
En
Revista:
Arch Med Sci
Ano de publicação:
2018
Tipo de documento:
Article
País de afiliação:
Polônia